Boston Scientific Co. (NYSE:BSX) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans raised its position in shares of Boston Scientific Co. (NYSE:BSX) by 71.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 333,963 shares of the medical equipment provider’s stock after acquiring an additional 139,392 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Boston Scientific were worth $25,718,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Sei Investments Co. raised its holdings in shares of Boston Scientific by 3.0% during the second quarter. Sei Investments Co. now owns 4,710,266 shares of the medical equipment provider’s stock valued at $362,739,000 after acquiring an additional 137,397 shares during the last quarter. AE Wealth Management LLC boosted its stake in Boston Scientific by 18.9% during the second quarter. AE Wealth Management LLC now owns 16,261 shares of the medical equipment provider’s stock worth $1,252,000 after buying an additional 2,582 shares during the last quarter. Simplify Asset Management Inc. grew its holdings in Boston Scientific by 27.5% in the 2nd quarter. Simplify Asset Management Inc. now owns 79,639 shares of the medical equipment provider’s stock valued at $6,133,000 after buying an additional 17,181 shares in the last quarter. Ieq Capital LLC increased its stake in shares of Boston Scientific by 10.8% in the 2nd quarter. Ieq Capital LLC now owns 63,338 shares of the medical equipment provider’s stock worth $4,878,000 after acquiring an additional 6,182 shares during the last quarter. Finally, Brighton Jones LLC raised its holdings in shares of Boston Scientific by 245.4% during the 2nd quarter. Brighton Jones LLC now owns 17,018 shares of the medical equipment provider’s stock worth $1,311,000 after acquiring an additional 12,091 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BSX shares. Truist Financial raised their price objective on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Citigroup upped their price objective on Boston Scientific from $90.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Morgan Stanley raised their target price on Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. The Goldman Sachs Group began coverage on Boston Scientific in a research note on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target on the stock. Finally, BTIG Research raised their price objective on Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $86.65.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total transaction of $517,579.96. Following the transaction, the executive vice president now owns 40,188 shares of the company’s stock, valued at $2,978,734.56. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 20,949 shares of company stock valued at $1,627,877. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 0.1 %

Shares of NYSE BSX opened at $84.00 on Tuesday. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $84.89. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The stock has a market cap of $123.24 billion, a P/E ratio of 70.59, a PEG ratio of 2.75 and a beta of 0.79. The business’s fifty day simple moving average is $78.84 and its 200-day simple moving average is $74.84.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The company had revenue of $4.12 billion for the quarter, compared to analysts’ expectations of $4.02 billion. During the same period last year, the firm earned $0.53 earnings per share. Boston Scientific’s quarterly revenue was up 14.5% on a year-over-year basis. As a group, equities analysts predict that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.